Horizon Therapeutics Public Limited Company

93.53-0.6200-0.66%Vol 155.48K1Y Perf 180.40%
Apr 23rd, 2021 10:38 DELAYED
BID93.37 ASK93.57
Open94.14 Previous Close94.15
Pre-Market- After-Market-
 - -%  - -
Target Price
115.80 
Analyst Rating
Strong Buy 1.06
Potential %
23.88 
Finscreener Ranking
★★★★+     58.22
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     53.87
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     75.52
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap20.96B 
Earnings Rating
Sell
Price Range Ratio 52W %
95.26 
Earnings Date
5th May 2021

Today's Price Range

93.2294.41

52W Range

33.0596.54

5 Year PE Ratio Range

-76.70111.60

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
0.94%
1 Month
9.24%
3 Months
21.12%
6 Months
21.58%
1 Year
180.40%
3 Years
575.39%
5 Years
474.44%
10 Years
-

TickerPriceChg.Chg.%
HZNP93.53-0.6200-0.66
AAPL133.411.47001.11
GOOG2 289.6221.70000.96
MSFT258.811.64000.64
XOM55.760.49000.89
WFC43.630.93002.18
JNJ165.340.16000.10
FB298.081.56000.53
GE13.590.18001.34
JPM149.542.17001.47
Financial StrengthValueIndustryS&P 500US Markets
3.10
3.50
0.20
0.25
7.70
Leverage Ratio 1.70
ProfitabilityValueIndustryS&P 500US Markets
75.80
15.10
29.90
-13.00
22.42
RevenueValueIndustryS&P 500US Markets
1.84B
8.23
25.45
17.83
Earnings HistoryEstimateReportedSurprise %
Q04 20201.051.2821.90
Q03 20201.001.7474.00
Q02 20200.400.437.50
Q01 20200.230.4491.30
Q04 20190.430.5630.23
Q03 20190.510.6425.49
Q02 20190.380.5236.84
Q01 20190.100.30200.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.19-17.39Negative
6/2021 QR0.84-10.64Negative
12/2021 FY3.52-18.14Negative
12/2022 FY4.98-18.23Negative
Next Report Date5th May 2021
Estimated EPS Next Report0.19
Estimates Count6
EPS Growth Next 5 Years %14.00
Volume Overview
Volume155.48K
Shares Outstanding224.07M
Trades Count2.20K
Dollar Volume336.40M
Avg. Volume1.89M
Avg. Weekly Volume994.18K
Avg. Monthly Volume1.53M
Avg. Quarterly Volume1.89M

Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) stock closed at 94.15 per share at the end of the most recent trading day (a 0.64% change compared to the prior day closing price) with a volume of 1.11M shares and market capitalization of 20.96B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 1395 people. Horizon Therapeutics Public Limited Company CEO is Timothy P. Walbert.

The one-year performance of Horizon Therapeutics Public Limited Company stock is 180.4%, while year-to-date (YTD) performance is 28.71%. HZNP stock has a five-year performance of 474.44%. Its 52-week range is between 33.05 and 96.54, which gives HZNP stock a 52-week price range ratio of 95.26%

Horizon Therapeutics Public Limited Company currently has a PE ratio of 55.50, a price-to-book (PB) ratio of 5.19, a price-to-sale (PS) ratio of 10.97, a price to cashflow ratio of 36.10, a PEG ratio of 2.32, a ROA of 7.15%, a ROC of 21.80% and a ROE of 12.17%. The company’s profit margin is 22.42%, its EBITDA margin is 29.90%, and its revenue ttm is $1.84 Billion , which makes it $8.23 revenue per share.

Of the last four earnings reports from Horizon Therapeutics Public Limited Company, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.19 for the next earnings report. Horizon Therapeutics Public Limited Company’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Horizon Therapeutics Public Limited Company is Strong Buy (1.06), with a target price of $115.8, which is +23.88% compared to the current price. The earnings rating for Horizon Therapeutics Public Limited Company stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Horizon Therapeutics Public Limited Company has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Horizon Therapeutics Public Limited Company has a Buy technical analysis rating based on Technical Indicators (ADX : 14.32, ATR14 : 4.16, CCI20 : 100.97, Chaikin Money Flow : 0.12, MACD : 2.09, Money Flow Index : 57.21, ROC : 4.62, RSI : 56.02, STOCH (14,3) : 77.96, STOCH RSI : 1.00, UO : 54.04, Williams %R : -22.04), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Horizon Therapeutics Public Limited Company in the last 12-months were: Andy Pasternak (Option Excercise at a value of $0), Barry J. Moze (Option Excercise at a value of $461 918), Barry J. Moze (Sold 166 271 shares of value $13 219 747 ), Brian K. Beeler (Option Excercise at a value of $419 666), Brian K. Beeler (Sold 90 724 shares of value $4 933 814 ), Daniel A. Camardo (Option Excercise at a value of $442 093), Daniel A. Camardo (Sold 16 400 shares of value $1 371 670 ), Geoffrey M. Curtis (Option Excercise at a value of $1 050 710), Geoffrey M. Curtis (Sold 92 657 shares of value $7 707 706 ), Gino Santini (Option Excercise at a value of $206 523), Gino Santini (Sold 12 000 shares of value $1 097 600 ), Irina P. Konstantinovsky (Option Excercise at a value of $1 140 087), Irina P. Konstantinovsky (Sold 103 481 shares of value $5 841 265 ), James S. Shannon (Option Excercise at a value of $88 158), James S. Shannon (Sold 7 232 shares of value $660 261 ), Jeff W. Himawan (Option Excercise at a value of $0), Jeffrey D. Kent (Option Excercise at a value of $215 980), Jeffrey D. Kent (Sold 50 729 shares of value $3 918 482 ), Jeffrey W. Sherman (Option Excercise at a value of $264 986), Jeffrey W. Sherman (Sold 146 421 shares of value $9 405 018 ), Michael DesJardin (Option Excercise at a value of $789 060), Michael DesJardin (Sold 92 313 shares of value $6 463 856 ), Michael G. Grey (Option Excercise at a value of $242 254), Michael G. Grey (Sold 46 590 shares of value $3 042 318 ), Miles W. Mchugh (Option Excercise at a value of $0), Miles W. Mchugh (Sold 117 012 shares of value $5 540 173 ), Pascale Witz (Option Excercise at a value of $0), Paul W. Hoelscher (Option Excercise at a value of $0), Paul W. Hoelscher (Sold 134 570 shares of value $6 230 473 ), Susan Mahony (Option Excercise at a value of $0), Thomas H. Watkins (Option Excercise at a value of $0), Timothy P. Walbert (Option Excercise at a value of $0), Timothy P. Walbert (Sold 359 502 shares of value $27 759 357 ), Vikram Karnani (Option Excercise at a value of $483 636), Vikram Karnani (Sold 132 612 shares of value $6 393 635 ), William F. Daniel (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (87.50 %)
7 (87.50 %)
8 (88.89 %)
Moderate Buy
1 (12.50 %)
1 (12.50 %)
1 (11.11 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.06
Strong Buy
1.06
Strong Buy
1.06

Horizon Therapeutics Public Limited Company

Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The company has two reportable segments: orphan and rheumatology segment and the inflammation segment. It markets medicines in the areas of orphan diseases, rheumatology and inflammation division. The majority of revenue is generated in the United States.

CEO: Timothy P. Walbert

Telephone: +353 17722100

Address: 1 Burlington Road, Dublin D04 C5Y6, , IE

Number of employees: 1 395

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

71%29%

Bearish Bullish

56%44%

Bearish Bullish

51%49%

News

Stocktwits